• Milestone Pharma
    Milestone Pharma
    • About Us
      • Leadership Team
      • Board of Directors
      • Careers
      • Contact Us
    • Areas of Focus
      • Paroxysmal supraventricular tachycardia (PSVT)
      • Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR)
    • Research & Development
      • Etripamil
      • Publications
      • Clinical Trials
      • Patient Access
    • Investors & Media
      • News & Events
      • Stock Information
      • Financial Information
      • Corporate Governance
      • Investor Resources
Milestone Pharma
Close
2
  • Milestone Pharma

Trends in Healthcare Resource Use and Expenditures in Patients with Newly Diagnosed Paroxysmal Supraventricular Tachycardia in the United States. 2021.

  • March 17, 2021
  • Publication
  • By Debbie Everidge
  • 0 Comments

This study explored the cost of health care spending in patients under the age of 65 three years before and three years after a PSVT…

2
  • Milestone Pharma

Disparities in the Management of Newly Diagnosed Paroxysmal Supraventricular Tachycardia for Women Versus Men in the United States. Journal of the American Heart Association. 2020.

  • March 17, 2021
  • Publication
  • By Debbie Everidge
  • 0 Comments

This study assesses gender differences in diagnosis, healthcare resource use, expenditures, and treatment.

Careers | Contact Us | Privacy Policy | Consumer Health Data Privacy Policy | Terms of Use
© Milestone Pharmaceuticals USA, Inc. All Rights Reserved.
  • English: United States
    • English: Canada
    • Français (French): Canada

Our website content is tailored by geographical region to comply with local regulatory requirements. Please select which country’s site you’d like to visit.

  • English: United States
  • English: Canada
  • Français (French): Canada